Lyon and Nantes (France), February 15, 2023 – 10:30 p.m. CET – ERYTECH Pharma (“ERYTECH”; Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drugs in red blood cells, and PHERECYDES Pharma (“PHERECYDES”; Euronext Growth: ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announced their planned strategic combination aimed at creating a global player in phage therapy and to accelerate the development of a pipeline of drug candidates, targeting pathogenic bacteria and other potential indications with significant unmet medical needs.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]